Get started
Author

Tamar Mordechai

Observed names: Mordechai, Tamar, T. Mordechai
OpenAlex ID: A5035538827
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study
2023 · Lital Friedman, Ofra-Barchad Avitzur, et al. · Expert Opinion on Drug Metabolism & Toxicology · 7
Poster: 232SPL84 integrity is preserved with ETI and inhaled CF therapies, supporting safety of combination use in pwCF with the 3849+10kb C→T variant
2026 · E. Ozeri-Galai, T. Mordechai, et al. · Journal of Cystic Fibrosis
Poster: 235SPL23, an exon-skipping antisense oligonucleotide for pwCF carrying the W1282X variant
2026 · Y. Cheng, Y. Oren, et al. · Journal of Cystic Fibrosis
Poster: 237SPL5AC, MUC5AC-lowering ASO for CF and other muco-obstructive lung diseases, restores lung function in a disease mouse model
2026 · N. Hara, E. Ozeri-Galai, et al. · Journal of Cystic Fibrosis
SPL5AC, MUC5AC lowering ASO for cystic fibrosis and other muco-obstructive diseases
2026 · E. Ozeri Galai, Y.S. Oren, et al. · Journal of Cystic Fibrosis
SPL84 and Trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variants
2026 · Yi Cheng, Yifat S. Oren, et al. · Journal of Cystic Fibrosis
222 SPL5B an ASO drug reducing MUC5B as a therapeutic approach for reducing mucus plugs in CF
2025 · E. Ozeri-Galai, Y. Oren, et al. · Journal of Cystic Fibrosis
221 SPL5AC, MUC5AC lowering ASO for CF and other muco-obstructive diseases
2025 · E. Ozeri-Galai, Y. Oren, et al. · Journal of Cystic Fibrosis
WS05.05SPL5AC, MUC5AC Lowering ASO for cystic fibrosis and other muco-obstructive diseases
2025 · E. Ozeri-Galai, Y.S. Oren, et al. · Journal of Cystic Fibrosis
277 SPL5AC an antisense oligonucleotide drug reducing MUC5AC as a therapeutic approach for CF and other muco-obstructive diseases
2024 · E. Ozeri-Galai, Y. Oren, et al. · Journal of Cystic Fibrosis
302 SPL84 preclinical studies supporting the phase 2 study design
2024 · E. Ozeri-Galai, Y. Oren, et al. · Journal of Cystic Fibrosis
EPS4.03 ASOs reducing MUC5AC or MUC5B as a therapeutic approach for CF and other muco-obstructive diseases
2024 · E. Ozeri Galai, Y.S. Oren, et al. · Journal of Cystic Fibrosis
235 Reducing MUC5AC or MUC5B expression using antisense oligonucleotides as a therapeutic approach for cystic fibrosis and other muco-obstructive diseases
2023 · Y. Oren, C. Stampfer, et al. · Journal of Cystic Fibrosis
PDF
231 Safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of people with cystic fibrosis with the 3849 +10 kb C- >T mutation to support Phase 1/2a clinical study
2023 · L. Friedman, O. Barchad-Avitzur, et al. · Journal of Cystic Fibrosis
PDF
615 Antisense oligonucleotide-based drug development for people with cystic fibrosis carrying the 2789+5 G-to-A splicing mutation
2022 · Y. Oren, O. Avizur Barchad, et al. · Journal of Cystic Fibrosis
PDF
620 Antisense oligonucleotide splicing modulation as a novel cystic fibrosis therapeutic approach for the N1303 K nonsense mutation
2022 · Y. Oren, O. Barchad-Avizur, et al. · Journal of Cystic Fibrosis
PDF
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation
2022 · Y.S. Oren, O. Avizur Barchad, et al. · Journal of Cystic Fibrosis
Works count: 18
Citation count: 7
H-index: 1
I10-index:
Year
Topic
Type